Floatz logo

Abexinostat

Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8

Rahul AggarwalSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

64 Active assets in the Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Dana-Farber Cancer Institute
Phase 4BB
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 3BB
Rapamycin
Dana-Farber Cancer Institute
Phase 4BB
Everolimus
Dana-Farber Cancer Institute
Phase 4BB
TECHNETIUM-99
Institut de Cancérologie de Lorraine
Phase 3BB

View all 50 →

Same molecule, other indications

Abexinostat is also rated in:

Hodgkins lymphomaDormant
B
Indicative ·
63 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
59 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →